Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Vanderbilt University Pfizer |
---|---|
Information provided by: | Vanderbilt University |
ClinicalTrials.gov Identifier: | NCT00713921 |
Develop and quantify methods for evaluating bladder dysfunction in diabetes and stroke
Condition | Intervention |
---|---|
Urinary Incontinence Bladder Dysfunction |
Drug: Detrol LA |
Study Type: | Interventional |
Study Design: | Diagnostic, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Neuropathic Investigation and Anticholinergic Treatment of Bladder Dysfunction in Diabetes and Stroke Patients |
Estimated Enrollment: | 20 |
Study Start Date: | February 2008 |
Estimated Study Completion Date: | December 2008 |
Estimated Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: Detrol LA
Oral Detrol LA, 4mg daily for sim months
|
Ages Eligible for Study: | 21 Years to 85 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Stroke Population:
Inclusion Criteria:
Diabetic Population:
Exclusion Criteria:
Stroke Population:
Diabetes Population:
Exclusion Criteria:
Contact: Barry K Jarnagin, MD | 615-771-7580 | barry.jarnagin@vanderbilt.edu |
United States, Tennessee | |
Vanderbilt Univiersity | Recruiting |
Nashville, Tennessee, United States, 37232-2519 | |
Contact: Lynne Black 615-343-9933 | |
Principal Investigator: Barry Jarnagin |
Principal Investigator: | Barry K Jarnagin, MD | Vanderbilt University |
Responsible Party: | Vanderbilt University ( Dr. Barry Jarnagin, Principal Investigator ) |
Study ID Numbers: | 051008 |
Study First Received: | July 9, 2008 |
Last Updated: | July 11, 2008 |
ClinicalTrials.gov Identifier: | NCT00713921 |
Health Authority: | United States: Institutional Review Board |
Female Diabetics Stroke |
Signs and Symptoms Urologic Diseases Cerebral Infarction Urination Disorders |
Stroke Diabetes Mellitus Urinary Incontinence Tolterodine |
Muscarinic Antagonists Urological Manifestations Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |
Cholinergic Antagonists Physiological Effects of Drugs Cholinergic Agents Pharmacologic Actions |